_id

69105913ccc777a4e85d572b

Ticker

DARE

Name

Dare Bioscience Inc

Exchange

NASDAQ

Address

3655 Nobel Drive, San Diego, CA, United States, 92122

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://darebioscience.com

Description

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Last Close

2.47

Volume

36175

Current Price

2.28

Change

-7.692307692307708

Last Updated

2025-11-29T12:07:30.321Z

Image

data:image/webp;base64,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

Ipo Date

2014-04-10T00:00:00.000Z

Market Cap

24802284

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.8531571428571428

Sentiment Sources

7

Rating

4.25

Target Price

10.75

Strong Buy

2

Buy

1

Hold

1

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

2262

Cost Of Revenue

612864

Gross Profit

-610602

Operating Expenses

3061546

Operating Income

-3672148

Interest Expense

213171

Pretax Income

-3562766

Net Income

-3562766

Eps

-0.27932063630644716

Dividends Per Share

-

Shares Outstanding

13479502

Income Tax Expense

-

EBITDA

-2736731

Operating Margin

-162340.76038903624

Total Other Income Expense Net

109382

Cash

23075261

Short Term Investments

-

Receivables

369157

Inventories

-

Total Current Assets

25004180

Property Plant Equipment

4726021

Total Assets

30748574

Payables

1844862

Short Term Debt

2478794

Long Term Debt

-

Total Liabilities

27890671

Equity

2857903

Depreciation

612864

Change In Working Capital

1918385

Cash From Operations

-442135

Capital Expenditures

174705

Cash From Investing

-174702

Cash From Financing

18650232

Net Change In Cash

18040255

PE

-

PB

10.175872085231722

ROE

-124.66364323771661

ROA

-11.586768218909924

FCF

-616840

Fcf Percent

-272.69672855879753

Piotroski FScore

1

Health Score

9

Deep Value Investing Score

3.5

Defensive Investing Score

5.5

Dividend Investing Score

1.5

Economic Moat Investing Score

3.3

Garp Investing Score

0.5

Growth Investing Score

0.5

Momentum Investing Score

2.5

Net Net Investing Score

2.5

Quality Investing Score

1.5

Value Investing Score

2

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

2262

Quarters > 0 > income Statement > cost Of Revenue

612864

Quarters > 0 > income Statement > gross Profit

-610602

Quarters > 0 > income Statement > operating Expenses

3061546

Quarters > 0 > income Statement > operating Income

-3672148

Quarters > 0 > income Statement > interest Expense

213171

Quarters > 0 > income Statement > pretax Income

-3562766

Quarters > 0 > income Statement > net Income

-3562766

Quarters > 0 > income Statement > eps

-0.27932063630644716

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

12755112

Quarters > 0 > income Statement > income Tax Expense

-

Quarters > 0 > income Statement > EBITDA

-2736731

Quarters > 0 > income Statement > operating Margin

-162340.76038903624

Quarters > 0 > income Statement > total Other Income Expense Net

109382

Quarters > 0 > balance Sheet > cash

23075261

Quarters > 0 > balance Sheet > short Term Investments

-

Quarters > 0 > balance Sheet > receivables

369157

Quarters > 0 > balance Sheet > inventories

-

Quarters > 0 > balance Sheet > total Current Assets

25004180

Quarters > 0 > balance Sheet > property Plant Equipment

4726021

Quarters > 0 > balance Sheet > total Assets

30748574

Quarters > 0 > balance Sheet > payables

1844862

Quarters > 0 > balance Sheet > short Term Debt

2478794

Quarters > 0 > balance Sheet > long Term Debt

-

Quarters > 0 > balance Sheet > total Liabilities

27890671

Quarters > 0 > balance Sheet > equity

2857903

Quarters > 0 > cash Flow > net Income

-3562766

Quarters > 0 > cash Flow > depreciation

612864

Quarters > 0 > cash Flow > change In Working Capital

1918385

Quarters > 0 > cash Flow > cash From Operations

-442135

Quarters > 0 > cash Flow > capital Expenditures

174705

Quarters > 0 > cash Flow > cash From Investing

-174702

Quarters > 0 > cash Flow > cash From Financing

18650232

Quarters > 0 > cash Flow > net Change In Cash

18040255

Quarters > 0 > ratios > PE

-0.27932063630644716

Quarters > 0 > ratios > PB

10.175872085231722

Quarters > 0 > ratios > ROE

-124.66364323771661

Quarters > 0 > ratios > ROA

-11.586768218909924

Quarters > 0 > ratios > FCF

-616840

Quarters > 0 > ratios > Piotroski FScore

1

Quarters > 0 > ratios > fcf Percent

-272.69672855879753

Quarters > 0 > health Score

9

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

-21172

Quarters > 1 > income Statement > cost Of Revenue

0

Quarters > 1 > income Statement > gross Profit

-21172

Quarters > 1 > income Statement > operating Expenses

3806628

Quarters > 1 > income Statement > operating Income

-3827800

Quarters > 1 > income Statement > interest Expense

268533

Quarters > 1 > income Statement > pretax Income

-4016483

Quarters > 1 > income Statement > net Income

-4016483

Quarters > 1 > income Statement > eps

-0.45275761724375235

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

8871155

Quarters > 1 > income Statement > income Tax Expense

-

Quarters > 1 > income Statement > EBITDA

-3367725

Quarters > 1 > income Statement > operating Margin

18079.5390137918

Quarters > 1 > income Statement > total Other Income Expense Net

-188683

Quarters > 1 > balance Sheet > cash

5035006

Quarters > 1 > balance Sheet > short Term Investments

-

Quarters > 1 > balance Sheet > receivables

188116

Quarters > 1 > balance Sheet > inventories

-

Quarters > 1 > balance Sheet > total Current Assets

6602417

Quarters > 1 > balance Sheet > property Plant Equipment

5307206

Quarters > 1 > balance Sheet > total Assets

12979525

Quarters > 1 > balance Sheet > payables

1762600

Quarters > 1 > balance Sheet > short Term Debt

2420095

Quarters > 1 > balance Sheet > long Term Debt

-

Quarters > 1 > balance Sheet > total Liabilities

25712785

Quarters > 1 > balance Sheet > equity

-12733260

Quarters > 1 > cash Flow > net Income

-4016483

Quarters > 1 > cash Flow > depreciation

460075

Quarters > 1 > cash Flow > change In Working Capital

-2475810

Quarters > 1 > cash Flow > cash From Operations

-5417456

Quarters > 1 > cash Flow > capital Expenditures

153396

Quarters > 1 > cash Flow > cash From Investing

153396

Quarters > 1 > cash Flow > cash From Financing

-43794

Quarters > 1 > cash Flow > net Change In Cash

-5294961

Quarters > 1 > ratios > PE

-0.45275761724375235

Quarters > 1 > ratios > PB

-1.588456797395168

Quarters > 1 > ratios > ROE

31.543241872073608

Quarters > 1 > ratios > ROA

-30.944761075617173

Quarters > 1 > ratios > FCF

-5570852

Quarters > 1 > ratios > Piotroski FScore

0

Quarters > 1 > ratios > fcf Percent

263.1235594180994

Quarters > 1 > health Score

48

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

25427

Quarters > 2 > income Statement > cost Of Revenue

2297381

Quarters > 2 > income Statement > gross Profit

-2271954

Quarters > 2 > income Statement > operating Expenses

2309164

Quarters > 2 > income Statement > operating Income

-4581118

Quarters > 2 > income Statement > interest Expense

-

Quarters > 2 > income Statement > pretax Income

-4378307

Quarters > 2 > income Statement > net Income

-4378307

Quarters > 2 > income Statement > eps

-0.49986379723712754

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

8759000

Quarters > 2 > income Statement > income Tax Expense

-

Quarters > 2 > income Statement > EBITDA

-4423008

Quarters > 2 > income Statement > operating Margin

-18016.745978684077

Quarters > 2 > income Statement > total Other Income Expense Net

202811

Quarters > 2 > balance Sheet > cash

10329967

Quarters > 2 > balance Sheet > short Term Investments

-

Quarters > 2 > balance Sheet > receivables

105234

Quarters > 2 > balance Sheet > inventories

-

Quarters > 2 > balance Sheet > total Current Assets

11822549

Quarters > 2 > balance Sheet > property Plant Equipment

5717865

Quarters > 2 > balance Sheet > total Assets

18618941

Quarters > 2 > balance Sheet > payables

1883142

Quarters > 2 > balance Sheet > short Term Debt

2319397

Quarters > 2 > balance Sheet > long Term Debt

-

Quarters > 2 > balance Sheet > total Liabilities

28182642

Quarters > 2 > balance Sheet > equity

-9563701

Quarters > 2 > cash Flow > net Income

-4378307

Quarters > 2 > cash Flow > depreciation

158110

Quarters > 2 > cash Flow > change In Working Capital

-1756004

Quarters > 2 > cash Flow > cash From Operations

-5470543

Quarters > 2 > cash Flow > capital Expenditures

157331

Quarters > 2 > cash Flow > cash From Investing

-157331

Quarters > 2 > cash Flow > cash From Financing

246577

Quarters > 2 > cash Flow > net Change In Cash

-5368207

Quarters > 2 > ratios > PE

-0.49986379723712754

Quarters > 2 > ratios > PB

-2.0881581304141563

Quarters > 2 > ratios > ROE

45.78046720615795

Quarters > 2 > ratios > ROA

-23.515338493204315

Quarters > 2 > ratios > FCF

-5627874

Quarters > 2 > ratios > Piotroski FScore

0

Quarters > 2 > ratios > fcf Percent

-221.33456561922367

Quarters > 2 > health Score

30

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

-63647

Quarters > 3 > income Statement > cost Of Revenue

14222534

Quarters > 3 > income Statement > gross Profit

-14286181

Quarters > 3 > income Statement > operating Expenses

-8897984

Quarters > 3 > income Statement > operating Income

-5388197

Quarters > 3 > income Statement > interest Expense

-

Quarters > 3 > income Statement > pretax Income

-5506398

Quarters > 3 > income Statement > net Income

-5506398

Quarters > 3 > income Statement > eps

-0.6480402494998234

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

8497000

Quarters > 3 > income Statement > income Tax Expense

-2

Quarters > 3 > income Statement > EBITDA

-5381829

Quarters > 3 > income Statement > operating Margin

8465.751724354644

Quarters > 3 > income Statement > total Other Income Expense Net

-118201

Quarters > 3 > balance Sheet > cash

15698174

Quarters > 3 > balance Sheet > short Term Investments

15682475826

Quarters > 3 > balance Sheet > receivables

229982

Quarters > 3 > balance Sheet > inventories

-

Quarters > 3 > balance Sheet > total Current Assets

18447863

Quarters > 3 > balance Sheet > property Plant Equipment

2542674

Quarters > 3 > balance Sheet > total Assets

22101131

Quarters > 3 > balance Sheet > payables

1455832

Quarters > 3 > balance Sheet > short Term Debt

548638

Quarters > 3 > balance Sheet > long Term Debt

-

Quarters > 3 > balance Sheet > total Liabilities

28113220

Quarters > 3 > balance Sheet > equity

-6012089

Quarters > 3 > cash Flow > net Income

-5506398

Quarters > 3 > cash Flow > depreciation

6368

Quarters > 3 > cash Flow > change In Working Capital

9991539

Quarters > 3 > cash Flow > cash From Operations

5226610

Quarters > 3 > cash Flow > capital Expenditures

562849

Quarters > 3 > cash Flow > cash From Investing

-562849

Quarters > 3 > cash Flow > cash From Financing

-132012

Quarters > 3 > cash Flow > net Change In Cash

4465565

Quarters > 3 > ratios > PE

-0.6480402494998234

Quarters > 3 > ratios > PB

-3.222367466616013

Quarters > 3 > ratios > ROE

91.58876390552435

Quarters > 3 > ratios > ROA

-24.91455301540903

Quarters > 3 > ratios > FCF

4663761

Quarters > 3 > ratios > Piotroski FScore

2

Quarters > 3 > ratios > fcf Percent

-73.27542539318428

Quarters > 3 > health Score

32

Valuation > metrics > PE

-0.27932063630644716

Valuation > metrics > PB

10.175872085231722

Valuation > final Score

20

Valuation > verdict

239.2% Overvalued

Profitability > metrics > ROE

-124.66364323771661

Profitability > metrics > ROA

-14.248681620433063

Profitability > metrics > Net Margin

-1575.051282051282

Profitability > final Score

0

Profitability > verdict

Weak

Risk > metrics > Debt Equity

9.759138431220373

Risk > metrics > Interest Coverage

-17.226301889093733

Risk > final Score

-63

Risk > verdict

High

Liquidity > metrics > Current Ratio

5.783110404713049

Liquidity > metrics > Quick Ratio

5.783110404713049

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

50

Prev Valuations > 1

50

Prev Valuations > 2

50

Prev Profitabilities > 0

70

Prev Profitabilities > 1

40

Prev Profitabilities > 2

70

Prev Risks > 0

-27

Prev Risks > 1

-380

Prev Risks > 2

-143

Prev Liquidities > 0

89

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-16T22:33:36.047Z